Media sources report on efforts by Johnson & Johnson to improve access to Sirturo, its medication for drug-resistant tuberculosis (TB).

Bloomberg News: J&J Eases Access for Tuberculosis Drug in Poor Nations
“Johnson & Johnson is taking steps to ensure Sirturo, its medicine for people with drug-resistant tuberculosis, is available and properly administered in 130 developing countries across the globe…” (Cortez, 4/29).

Johnson & Johnson: Johnson & Johnson Announces New Collaboration with Stop TB Partnership’s Global Drug Facility to Enhance Access to Anti-TB Compound
“Johnson & Johnson [Tuesday] announced that its affiliate Janssen Pharmaceutica NV (Janssen) has entered into a novel collaboration with the Stichting International Dispensary Association (IDA), a procurement agent for the Stop TB Partnership’s Global Drug Facility (GDF), to facilitate access to the company’s anti-tuberculosis medicine. This public-private partnership was established by the newly formed Janssen Global Public Health and is the latest in the company’s overall efforts to improve public health…” (4/29).